Regulator of G protein signaling is a crucial modulator of antidepressant drug action in depression and neuropathic pain models

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 20, 2013, Pages 8254-8259

  Stratinaki, Maria ^a   Varidaki, Artemis ^a   Mitsi, Vasiliki ^a   Ghose, Subroto ^b   Magida, Jane ^c   Dias, Caroline ^c   Russo, Scott J ^c   Vialou, Vincent ^c   Caldarone, Barbara J ^d   Tamminga, Carol A ^b   Nestler, Eric J ^c   Zachariou, Venetia ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adeno associated viruses; Conditional knockout mice; Desipramine; Mood disorders

Indexed keywords

ANTIDEPRESSANT AGENT; DELTA OPIATE RECEPTOR AGONIST; DESIPRAMINE; GLUTAMATE RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; RGS PROTEIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; FEMALE; FORCED SWIMMING TEST; GENE SILENCING; GENE TRANSFER; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESISTANT DEPRESSION;

ADENO-ASSOCIATED VIRUSES; CONDITIONAL KNOCKOUT MICE; DESIPRAMINE; MOOD DISORDERS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; DESIPRAMINE; FEMALE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MOOD DISORDERS; NEURALGIA; RGS PROTEINS; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84877862396     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1214696110     Document Type: Article

References (38)

1. Argoff CE (2007) The coexistence of neuropathic pain, sleep, and psychiatric disorders: A novel treatment approach. Clin J Pain 23(1):15-22.
2. Taymans JM, et al. (2004) Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur J Neurosci 19(8):2249-2260.
3. Ding J, et al. (2006) RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 9(6): 832-842.
4. Gold SJ, et al. (2003) Regulation of RGS proteins by chronic morphine in rat locus coeruleus. Eur J Neurosci 17(5):971-980. (Pubitemid 36411594)
5. Georgoussi Z, et al. (2006) Selective interactions between G protein subunits and RGS4 with the C-terminal domains of the mu-and delta-opioid receptors regulate opioid receptor signaling. Cell Signal 18(6):771-782. (Pubitemid 43210445)
6. Volk DW, Eggan SM, Lewis DA (2010) Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 167(12):1489-1498.
7. Gu Z, Jiang Q, Yan Z (2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71(4):1030-1039. (Pubitemid 46457007)
8. Liu W, et al. (2006) Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin. Proc Natl Acad Sci USA 103(48):18338-18343. (Pubitemid 44871659)
9. Cavalli A, Druey KM, Milligan G (2000) The regulator of G protein signaling RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase activity of Go1alpha and Gi2alpha. J Biol Chem 275(31):23693-23699. (Pubitemid 30624654)
10. Hollinger S, Hepler JR (2002) Cellular regulation of RGS proteins: Modulators and integrators of G protein signaling. Pharmacol Rev 54(3):527-559.
11. Terzi D, Stergiou E, King SL, Zachariou V (2009) Regulators of G protein signaling in neuropsychiatric disorders. Prog Mol Biol Transl Sci 86:299-333.
12. Levitt P, Ebert P, Mirnics K, Nimgaonkar VL, Lewis DA (2006) Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry 60(6):534-537. (Pubitemid 44402383)
13. Buckholtz JW, et al. (2007) Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 27(7):1584-1593. (Pubitemid 46280076)
14. Ding L, Hegde AN (2009) Expression of RGS4 splice variants in dorsolateral prefrontal cortex of schizophrenic and bipolar disorder patients. Biol Psychiatry 65(6):541-545.
15. Lerner TN, Kreitzer AC (2012) RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 73(2):347-359.
16. Gold SJ, Ni YG, Dohlman HG, Nestler EJ (1997) Regulators of G-protein signaling (RGS) proteins: Region-specific expression of nine subtypes in rat brain. J Neurosci 17(20): 8024-8037. (Pubitemid 27426238)
17. Ni YG, et al. (1999) Region-specific regulation of RGS4 (Regulator of G-proteinsignaling protein type 4) in brain by stress and glucocorticoids: In Vivo and in vitro studies. J Neurosci 19(10):3674-3680. (Pubitemid 29222243)
18. Han MH, et al. (2010) Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry 67(8):761-769.
19. Carlezon WA, Jr., Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28(8):436-445. (Pubitemid 40982557)
20. Covington HE, 3rd, et al. (2011) A role for repressive histone methylation in cocaineinduced vulnerability to stress. Neuron 71(4):656-670.
21. Matsuzawa-Yanagida K, et al. (2008) Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 33(8):1952-1965. (Pubitemid 351832604)
22. Broom DC, et al. (2002) Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26(6):744-755. (Pubitemid 34455027)
23. Berman RM, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351-354. (Pubitemid 30109248)
24. Li N, et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959-964.
25. aan het Rot M, et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psych 67(2):139-145.
26. DiazGranados N, et al. (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71(12):1605-1611.
27. Murrough JW, Perez AM, Mathew SJ, Charney DS (2011) A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry 72(3):414-415.
28. Blonk MI, Koder BG, van den Bemt PM, Huygen FJ (2010) Use of oral ketamine in chronic pain management: A review. Eur J Pain 14(5):466-472.
29. Taymans JM, Leysen JE, Langlois X (2003) Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: Clues for RGS2 and RGS4 functions. J Neurochem 84(5):1118-1127. (Pubitemid 36330664)
30. Schwendt M, McGinty JF (2007) Regulator of G-protein signaling 4 interacts with metabotropic glutamate receptor subtype 5 in rat striatum: Relevance to amphetamine behavioral sensitization. J Pharmacol Exp Ther 323(2):650-657. (Pubitemid 350005138)
31. Saugstad JA, Marino MJ, Folk JA, Hepler JR, Conn PJ (1998) RGS4 inhibits signaling by group I metabotropic glutamate receptors. J Neurosci 18(3):905-913. (Pubitemid 28112913)
32. Schwendt M, Sigmon SA, McGinty JF (2012) RGS4 overexpression in the rat dorsal striatum modulates mGluR5-and amphetamine-mediated behavior and signaling. Psychopharmacology (Berl) 221(4):621-635.
33. Turner EM, Blazer LL, Neubig RR, Husbands SM (2012) Small molecule inhibitors of regulator of G protein signalling (RGS) proteins. ACS Med Chem Lett 3(2):146-150.
34. Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V (2012) R7BP modulates opiate analgesia and tolerance but not withdrawal. Neuropsychopharmacology 37(4): 1005-1012.
35. Krishnan V, et al. (2008) Calcium-sensitive adenylyl cyclases in depression and anxiety: Behavioral and biochemical consequences of isoform targeting. Biol Psychiatry 64(4): 336-343.
36. Onksen JL, Brown EJ, Blendy JA (2011) Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect. Neuropsychopharmacology 36(5):960-969.
37. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ (2003) Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med 9(12): 1539-1544. (Pubitemid 38004783)
38. Stan AD, et al. (2006) Human postmortem tissue: What quality markers matter? Brain Res 1123(1):1-11.